OceanTech Acquisitions I Corp and Captura Biopharma Sign Definitive Business Combination Agreement

Atlantic Coastal Acquisition Corp. II Completes Business Combination with Abpro Corporation

November 13, 2024

Biotechnology

Abpro Corporation and Atlantic Coastal Acquisition Corp. II completed their business combination and the combined company will operate as Abpro Holdings, Inc., with Abpro Corporation as a wholly owned subsidiary. The company is expected to begin trading on Nasdaq under the ticker ABP (and ABPWW for warrants); South Korea's Celltrion participated in a $5.0 million PIPE and appointed Soo Young Lee to Abpro's board.

OceanTech Acquisitions I Corp. to Combine with Majic Wheels Corp. (Majic Corp.)

November 15, 2022

Financial Services

OceanTech Acquisitions I Corp. and Majic Wheels Corp. entered into a definitive business combination agreement under which Majic Wheels will become a publicly listed company on Nasdaq. Upon closing, OceanTech will be renamed Majic Corp. with an expected transaction value of approximately $200 million and a forward share purchase backstop of up to $40 million by Meteora Capital Partners.

SAB Biotherapeutics to Go Public via Merger with Big Cypress Acquisition Corp.

October 20, 2021

Biotechnology

SAB Biotherapeutics entered into a definitive business combination/merger agreement with Big Cypress Acquisition Corp. (a SPAC), with the combined company to operate as SAB Biotherapeutics and be listed on Nasdaq. Big Cypress stockholders approved the deal, and the transaction was expected to close on or about October 22, 2021, subject to customary conditions.

Investcorp Europe Acquisition Corp I and OpSec Group Business Combination to Take OpSec Public

April 26, 2023

Cybersecurity

OpSec Group and Investcorp Europe Acquisition Corp I entered into a definitive business combination agreement that would take OpSec Group public on Nasdaq. The combined company would operate as OpSec Group, with the transaction expected to close in the second half of 2023 and supported by a $50 million sponsor backstop and up to $199 million in gross proceeds subject to redemptions.

Comera Life Sciences to Go Public via Business Combination with OTR Acquisition Corp.

January 31, 2022

Healthcare Services

Comera Life Sciences entered into a business combination agreement with publicly traded special purpose acquisition company OTR Acquisition Corp. to become a publicly listed company. The transaction is expected to provide Comera with access to public equity markets and approximately $107 million in gross proceeds (subject to redemptions).

Voyager Acquisition Corp and VERAXA Biotech Announce Form F-4 Filing for Proposed Business Combination

July 17, 2025

Healthcare Services

VERAXA Biotech AG and Voyager Acquisition Corp. (a SPAC) have filed a Form F-4 registration statement with the SEC in connection with their proposed business combination announced in April 2025. Under the terms, VERAXA shareholders are expected to roll over 100% of their equity and receive approximately 130 million ordinary shares of the combined company, with the deal expected to close in Q4 2025.